AstraZeneca inks mRNA production deal with CanSino

2023-08-09

疫苗临床2期信使RNA

AstraZeneca has reached an agreement for CanSino Biologics to provide it with manufacturing services related to the potential development of mRNA vaccines, according to a Shanghai stock exchange filing by the Chinese vaccine developer. Financial details of the deal were not disclosed, but CanSino said it would manufacture and supply unspecified mRNA products to AstraZeneca.

The UK drugmaker said the agreement would support experimental mRNA shots in its early pipeline. The company added that it was working on "next-generation technologies" to develop vaccines and monoclonal antibodies for infectious diseases where there was high unmet need, and that it would " share further details as proof-of-concept is achieved and the candidates progress."

Last year, AstraZeneca ended an mRNA partnership with Moderna on AZD860 in cardiovascular disease despite the drug having succeeded in a Phase II heart failure study in 2021. The mRNA candidate was designed to stimulate VEGF-A production.

Meanwhile, on a visit to China earlier this year, AstraZeneca CEO Pascal Soriot lauded the potential for investing in Chinese biotech, including through acquisitions and partnerships. The CanSino tie-up comes shortly after China's commerce minister Wang Wentao told foreign pharmaceutical firms, including AstraZeneca, at a recent meeting that they can expect "more development opportunities."

China approved its first domestic mRNA-based COVID vaccine, developed by CSPC Pharmaceutical, in March. Meanwhile, CanSino has been working on its own mRNA jab against COVID, announcing earlier this year that it was in discussions with Chinese regulators around the protocol for a late-stage study for its COVID mRNA booster jab CS-2034.

Moderna, which has also indicated that it was keen to sell its mRNA vaccine to China, itself recently announced a deal to develop and manufacture mRNA medicines in the country.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构